A new hope for Amarin? Vascepa generic settlement leaves analysts split on patent appeal success

A new hope for Amarin? Vascepa generic settlement leaves analysts split on patent appeal success

Source: 
Fierce Pharma
snippet: 

Eyeing blockbuster sales for its cardiovascular drug Vascepa, Amarin took a nightmarish hit in March when a federal judge struck down key patents. Now, in its quest to overturn that ruling, the company has snagged a settlement with one generic challenger—but analysts are split on whether that deal portends a win for Amarin on appeal.